Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.

Darrah PA, DiFazio RM, Maiello P, Gideon HP, Myers AJ, Rodgers MA, Hackney JA, Lindenstrom T, Evans T, Scanga CA, Prikhodko V, Andersen P, Lin PL, Laddy D, Roederer M, Seder RA, Flynn JL.

NPJ Vaccines. 2019 May 28;4:21. doi: 10.1038/s41541-019-0113-9. eCollection 2019.

2.

Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies.

Fitzpatrick M, Ho MM, Clark S, Dagg B, Khatri B, Lanni F, Williams A, Brennan M, Laddy D, Walker B.

Tuberculosis (Edinb). 2019 Jan;114:47-53. doi: 10.1016/j.tube.2018.10.013. Epub 2018 Nov 2.

3.

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.

Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ.

Nat Med. 2018 Feb;24(2):130-143. doi: 10.1038/nm.4473. Epub 2018 Jan 15.

4.

Toward Tuberculosis Vaccine Development: Recommendations for Nonhuman Primate Study Design.

Laddy DJ, Bonavia A, Hanekom WA, Kaushal D, Williams A, Roederer M, Seder RA, Sharpe S, Verreck FAW, Darrah PA.

Infect Immun. 2018 Jan 22;86(2). pii: e00776-17. doi: 10.1128/IAI.00776-17. Print 2018 Feb.

5.

Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.

Lahey T, Laddy D, Hill K, Schaeffer J, Hogg A, Keeble J, Dagg B, Ho MM, Arbeit RD, von Reyn CF.

PLoS One. 2016 Dec 20;11(12):e0168521. doi: 10.1371/journal.pone.0168521. eCollection 2016.

6.

Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype.

Smith CM, Proulx MK, Olive AJ, Laddy D, Mishra BB, Moss C, Gutierrez NM, Bellerose MM, Barreira-Silva P, Phuah JY, Baker RE, Behar SM, Kornfeld H, Evans TG, Beamer G, Sassetti CM.

MBio. 2016 Sep 20;7(5). pii: e01516-16. doi: 10.1128/mBio.01516-16.

7.

Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques.

Sharpe S, White A, Gleeson F, McIntyre A, Smyth D, Clark S, Sarfas C, Laddy D, Rayner E, Hall G, Williams A, Dennis M.

Tuberculosis (Edinb). 2016 Jan;96:1-12. doi: 10.1016/j.tube.2015.10.004. Epub 2015 Nov 6.

8.

Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Villarreal DO, Walters J, Laddy DJ, Yan J, Weiner DB.

Hum Vaccin Immunother. 2014;10(8):2188-98. doi: 10.4161/hv.29574.

9.

Nuclear imaging: a powerful novel approach for tuberculosis.

Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S.

Nucl Med Biol. 2014 Nov-Dec;41(10):777-84. doi: 10.1016/j.nucmedbio.2014.08.005. Epub 2014 Aug 7. Review.

10.

Nonclinical Development of BCG Replacement Vaccine Candidates.

Velmurugan K, Grode L, Chang R, Fitzpatrick M, Laddy D, Hokey D, Derrick S, Morris S, McCown D, Kidd R, Gengenbacher M, Eisele B, Kaufmann SH, Fulkerson J, Brennan MJ.

Vaccines (Basel). 2013 Apr 16;1(2):120-38. doi: 10.3390/vaccines1020120.

11.

Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets.

Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, Weiner DB, von Messling V, Kobinger GP.

Vaccine. 2011 Sep 9;29(39):6793-801. doi: 10.1016/j.vaccine.2010.12.059. Epub 2011 Jan 4.

PMID:
21211587
12.

Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells.

Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, Wu L, Chung CW, Lankaraman KM, Burns J, Muthumani K, Weiner DB.

Immunology. 2009 Sep;128(1 Suppl):e612-20. doi: 10.1111/j.1365-2567.2009.03044.x. Epub 2009 Jan 12.

13.

High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model.

Yin J, Dai A, Laddy DJ, Yan J, Arango T, Khan AS, Lewis MG, Andersen H, Kutzler MA, Draghia-Akli R, Weiner DB, Boyer JD.

Virology. 2009 Oct 10;393(1):49-55. doi: 10.1016/j.virol.2009.07.017. Epub 2009 Aug 15.

14.

Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.

Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, Weiner DB.

Hum Gene Ther. 2009 Oct;20(10):1143-56. doi: 10.1089/hum.2009.025.

15.

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity.

Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, Weiner DB.

Blood. 2009 Jun 4;113(23):5868-77. doi: 10.1182/blood-2008-11-190520. Epub 2009 Mar 20.

16.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB.

J Virol. 2009 May;83(9):4624-30. doi: 10.1128/JVI.02335-08. Epub 2009 Feb 11.

17.

Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism.

Muthumani K, Choo AY, Shedlock DJ, Laddy DJ, Sundaram SG, Hirao L, Wu L, Thieu KP, Chung CW, Lankaraman KM, Tebas P, Silvestri G, Weiner DB.

J Virol. 2008 Dec;82(23):11536-44. doi: 10.1128/JVI.00485-08. Epub 2008 Sep 17.

18.

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB.

PLoS One. 2008 Jun 25;3(6):e2517. doi: 10.1371/journal.pone.0002517.

19.

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.

Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB.

Vaccine. 2008 Sep 19;26(40):5128-34. doi: 10.1016/j.vaccine.2008.03.060. Epub 2008 Apr 14.

20.

Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Laddy DJ, Yan J, Corbitt N, Kobinger GP, Weiner DB.

Vaccine. 2007 Apr 20;25(16):2984-2989. doi: 10.1016/j.vaccine.2007.01.063. Epub 2007 Jan 30.

21.

From plasmids to protection: a review of DNA vaccines against infectious diseases.

Laddy DJ, Weiner DB.

Int Rev Immunol. 2006 May-Aug;25(3-4):99-123. Review.

PMID:
16818367
22.

HIV-1 Vpr and anti-inflammatory activity.

Muthumani K, Desai BM, Hwang DS, Choo AY, Laddy DJ, Thieu KP, Rao RG, Weiner DB.

DNA Cell Biol. 2004 Apr;23(4):239-47. Review.

PMID:
15142381
23.

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.

Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB.

Vaccine. 2004 Apr 16;22(13-14):1782-90.

PMID:
15068862

Supplemental Content

Support Center